BD Reports Third Quarter Fiscal 2026 Financial Results
BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.
How this was made
The 30-second read
Why it matters
BDX’s Q3 performance and raised full-year guidance (revenue growth toward the high end of the range, higher adjusted EPS midpoint) are the primary catalysts. The contract award, GLP-1 pen platform collaboration, and new laser system launch add qualitative support for growth platforms.
Market read
Traders can use the raised adjusted EPS midpoint and the cited FCF improvement to update earnings and cash-flow expectations ahead of the earnings call.
What to watch
The excerpt omits segment-level margin and cash flow drivers; traders should verify whether the FCF increase is recurring (working capital) or one-off, and how the spin-off and Waters combination affect comparability.
Background
BD completed a spin-off and combined the former Biosciences and Diagnostic Solutions business with Waters on Feb. 9, 2026; this release presents results on a continuing-operations basis.
Ticker impact
BDX reported fiscal 2026 Q3 revenue of $5.0B and GAAP/adjusted EPS from continuing operations, and raised the adjusted EPS guidance midpoint.
Likely positive bias for the next session and into the earnings call as traders reprice full-year EPS and FCF trajectory.
The article discloses specific Q3 results and an explicit full-year guidance update (revenue high-end range and higher adjusted EPS midpoint), which typically drives repricing even without detailed segment tables in the excerpt.
Market effects
Signals continued demand and execution in MedTech platforms (insertion systems, GLP-1 delivery, urology lasers), which can support sentiment across medical devices.
Limited in the excerpt; FX-neutral growth is cited, implying currency is a secondary driver versus underlying demand.
GLP-1 access expansion via Brazil collaboration highlights ongoing global scale-up of obesity and diabetes therapies, relevant to MedTech supply chains.
Counterpoint
Adjusted EPS excludes various potential charges/gains; if GAAP results or margin sustainability disappoint on the call, the guidance raise may be partially offset.
Key entities
- companyBD (Becton, Dickinson and Company)
Reported fiscal 2026 Q3 results, updated full-year guidance, and highlighted growth-platform wins and launches.
- customer/contracting entityVizient
Awarded a Vizient Innovative Technology contract for BD’s CentroVena One Insertion System.
- partnerEMS (Brazil)
Collaborated with BD to expand access to GLP-1 therapies using BD’s Vystra Injection Pen platform.
- partner/transaction counterpartyWaters Corporation
Combined with BD’s former Biosciences and Diagnostic Solutions business as part of the Feb. 9, 2026 transaction.
